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FACTORS AFFECTING HEME TRANSFER FROM “GAPDH”, A 
POSSIBLE HEME CARRIER PROTEIN 
 
RAJESH VEMPATI 
 
ABSTRACT 
 
The aim of my research is to understand the mechanism of heme transfer by 
carrier proteins into heme proteins. The mechanism of heme insertion into proteins 
is poorly understood. Previous experiments reported from our lab identified 
GAPDH as a possible heme carrier protein involved in heme transfer (Ritu 
Chakravarti et al PNAS). This work focuses on 2 aspects of heme transfer. a.) Rate 
of transfer of heme from GAPDH to apomyoglobin. We examined the rate of 
transfer of native proto-heme and the analogue meso-heme. The results showed 
that the rate of heme transfer was twice as fast for meso-heme compared to the 
native proto-heme, for both human and rabbit GAPDH’s. This suggests that 
structural factors may be important for heme transfer from GAPDH to apo-
myoglobin.   
b.) Nitrosylation of GAPDH and its effect on rate of heme transfer. We went on to 
examine different factors that could affect the extent of nitrosylation. The factors 
which we examined were dose of nitrosylation donor, pH, and stability of 
nitrosylated protein with temperature and presence of oxygen. 1.) Increasing the 
dose of nitrosylation donor increased the extent of nitrosylation in the case of 
 v
human GAPDH, in contrary with rabbit GAPDH nitrosylation which is not 
dependent on dose 2.) Nitrosylated protein is more stable at 4oC than at room 
temperature. 3.) The extent of nitrosylation increased as the pH increases in case 
of rabbit GAPDH, however human GAPDH nitrosylation was favored at slightly 
acidic and alkaline compared to neutral pH. Reducing agents like DTT, tertiary 
amines like HEPES buffer and oxygen were found to have no effect on extent of 
nitrosylation. Previous cell biology work from our lab suggests that nitrosylation 
of Cys152 in vivo diminishes heme binding property of GAPDH. Cysteine 
residues that underwent nitrosylation were identified by mass spectrometry. The 
results from mass spectrometry suggest that the levels of nitrosylation on each 
individual cysteine are species-specific. In fact, rabbit and human GAPDH showed 
different levels of nitrosylation. In parallel site-directed mutagenesis was used to 
determine which one of the nitrosylated cysteine mutants had an effect on the rate 
of heme transfer. The results suggest that nitrosylation of wild type and different 
point mutants of GAPDH doesn’t affect the rate of heme transfer, indicating that 
there is no substantial effect of S-nitrosylation on rate of heme transfer (Mild 
increase in rate of heme delivery for 2 cysteine mutants, C152/156S and C156S 
after nitrosylation). 
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CHAPTER I 
INTRODUCTION 
 
1.1 Heme proteins: 
Heme proteins are important proteins which play vital roles in physiology such as 
free radical elimination, signal transduction, oxygen transport, and electron 
transfer. Heme exists as a prosthetic group in several heme proteins, heme is an 
essential regulator of gene expression (1). The most common heme type is Fe-
protoporphyrin which is heme B and others include A, C and O which are less 
common (2, 3).  The last step in heme biosynthesis is the insertion of an iron atom 
into protoporphyrin which is catalyzed by ferrochelatase in the mitochondria (4, 
5). Free heme is toxic to cells since it can cause damage to DNA, proteins and 
lipids by generating reactive oxygen species (ROS) therefore, cells keep tight 
control on free heme (6). Until now there is no confirmation how heme travels 
from mitochondria to heme proteins like myoglobin, hemoglobin, NOS and 
guanylate cyclase which are present in cytosol. A protein carrier involved in 
transporting heme from mitochondria to heme proteins has been proposed but yet 
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to be confirmed, until now there is no established pathway how heme gets 
incorporated into heme proteins.   
 
1.2 Mechanism of heme delivery: 
Previous studies in our lab about heme insertion into heme proteins such as 
myoglobin, hemoglobin and NOS suggest the role of carrier proteins in heme 
insertion (7). Previous research in our lab suggested that two proteins are 
important for heme insertion into apo-protein targets: Hsp90 and GAPDH. Heat 
shock protein (hsp90) plays a role in enabling heme insertion into cytokine 
inducible mouse NOS. Studies showed hsp90 was associated more with heme free 
iNOS, as compared to heme containing iNOS. Also, kinetic data suggested that 
cellular heme insertion coincided with hsp90 dissociation. The data also suggests 
that ATP deficient hsp90 blocked cellular heme insertion into heme free iNOS, 
Together, these observations suggest a potential role of hsp90 in cellular heme 
insertion into iNOS (8).   
There are notable interactions between iNOS and GAPDH as determined by 
surface plasmon resonance, which suggests that GAPDH is a possible heme carrier 
protein to iNOS. It was also proposed that nitrosylation at Cys152 on GAPDH 
diminished the heme binding property of GAPDH  (9).  
GAPDH is one of the key enzymes in glycolysis. GAPDH catalyzes the 
conversion of glyceraldehyde-3-phosphate to high energy phosphate 1, 3-
bisphosphoglycerate which is reversible and also first step in glycolysis (10). 
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GAPDH is involved in apoptosis, transcription activation, and may be heme 
carrier protein (11-14). GAPDH exists as a tetramer of 4 identical polypeptides 
each of 37kDa approximately. The human protein has 335-aminoacid, whereas in 
rabbit it is 333-aminoacid per monomer. Four subunits, which are designated as O, 
P, Q and R form the homotetrameric human liver GAPDH, which has 3 non-
equivalent interfaces P, Q, and R. Fo-Fc difference map shows positive density 
around the active-site cysteine 152 of all 4 subunits. Rabbit skeletal muscle 
GAPDH is also very similar to human GAPDH as their sequence similarity was 
very high. The alignment shows 99% similarity between human and rabbit 
GAPDH which is represented in Fig.1.1  
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Accession numbers for the protein sequences:  
 
Human GAPDH: P04406 
Rabbit GAPDH: P46406 
 
Query  2    VKVGVNGFGRIGRLVTRAAFNSGKVDVVAINDPFIDLHYMVYMFQYDSTHGKFHGTVKAE  61 
            VKVGVNGFGRIGRLVTRAAFNSGKVD+VAINDPFIDL+YMVYMFQYDSTHGKFHGTVKAE 
Sbjct  4    VKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVKAE  63 
 
Query  62   NGKLVINGKAITIFQERDPANIKWGDAGAEYVVESTGVFTTMEKAGAHLKGGAKRVIISA  121 
            NGKLVING  ITIFQERDP+ IKWGDAGAEYVVESTGVFTTMEKAGAHL+GGAKRVIISA 
Sbjct  64   NGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISA  123 
 
Query  122  PSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDHFGIVEGLMTTVHAITA  181 
            PSADAPMFVMGVNHEKYDNSLKI+SNASCTTNCLAPLAKVIHD+FGIVEGLMTTVHAITA 
Sbjct  124  PSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITA  183 
 
Query  182  TQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTPNVSVV  241 
            TQKTVDGPSGKLWRDGRGA QNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPT NVSVV 
Sbjct  184  TQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVSVV  243 
 
Query  242  DLTCRLEKAAKYDDIKKVVKQASEGPLKGILGYTEDQVVSCDFNSATHSSTFDAGAGIAL  301 
            DLTCRLEK AKYDDIKKVVKQASEGPLKGILGYTE QVVS DFNS THSSTFDAGAGIAL 
Sbjct  244  DLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIAL  303 
 
Query  302  NDHFVKLISWYDNEFGYSNRVVDLMVHMASKE  333 
            NDHFVKLISWYDNEFGYSNRVVDLM HMASKE 
Sbjct  304  NDHFVKLISWYDNEFGYSNRVVDLMAHMASKE  335 
 
Query= rabbit GAPDH 
Sbjct= human  GAPDH 
 
Fig.1.1. The above figure represents the alignment of human and rabbit GAPDH and the 
highlighted residues represent cysteines. The alignment was carried out using the blast tool at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. 
 
 However there are certain differences as in case of human GAPDH each subunit 
is bound to NAD+ and in the case of rabbit skeletal GAPDH only 2 subunits P and 
R binds to NAD+. The other difference is in their side-chain conformation of 
Arg234. Two residues, cysteine152 and histidine179 play major roles in catalysis. 
Cysteine152 provides a sulfhydryl group for nucleophilic effect on G3P and 
histidine179 functions as a base catalyst to facilitate hydride transfer (15, 16). Our 
lab has found that the catalytic properties of GAPDH are not affected by heme 
binding (Unpublished data).  
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Fig.1.2. Crystal structure of human GAPDH, tetramer protein having 4 identical monomers. Each 
monomer has 3 cysteines which are shown above at 152, 156 and 247. Cysteine 152 is 
responsible for GAPDH activity.  
 
 
 
          
 
 
 
 
 
5  
6  
 
 
Rabbit muscle GAPDH crystal structure 
 
 
 
Fig.1.3. Crystal structure of rabbit muscle GAPDH, Tetramer having four identical monomers 
and having close similarity to human GAPDH. Four cysteines are present at 150, 154, 244 and 
282. Here cysteine 150 is not shown.  
 
This project deals with rate of heme transfer from GAPDH to apomyoglobin. We 
set up an assay to determine the rate of heme transfer from GAPDH heme 
complex to Apo myoglobin. We considered different factors, which may have an 
effect on the rate of heme transfer from GAPDH-heme complex. The mutant Apo 
myoglobin glycerol stock was obtained from Dr. John S. Olson (Rice University, 
Texas, USA). 
Myoglobin is a monomeric heme protein which is present mainly in muscle tissues 
because of its ability to bind oxygen and store it. It is a single chain globular 
protein with 154 aminoacids containing heme prosthetic group in its center. The 
molecular weight of our mutant is 17.4kDa. It is made of 8 alpha helices joined by 
Absor
bance 
of
c154
 c282
c244 
 
 
short loops, and is water soluble. Each myoglobin has 1 heme prosthetic group 
inserted into a hydrophobic cleft in protein. The hydrophobic interactions between 
hydrophobic aminoacid group present in the interior side of the cleft and 
tetrapyrrole ring stabilize the heme binding to protein (17, 18). Heme binding to 
the protein is also stabilized by an axial nitrogen atom provided by histidine 93 at 
2.09 angstroms from iron-heme; the iron is also chelated by histidine 64. Our lab 
use a mutant form of apo-myoglobin that has an increased affinity for heme 
(molecular weight =17.4 K Da). In the mutant apomyoglobin, His 64 is replaced 
with Tyr to increase its affinity for heme. Val68 is replaced with phenylalanine 
which makes it stable (19, 20). 
 
Crystal Structure of Sperm whale myoglobin 
 
 
 
 
 
Fig.1.4. Crystal structure of sperm whale myoglobin, Histidine 64 has been replaced by tyrosine 
to increase the affinity towards the heme. The heme is represented in yellow. All crystallographic 
images were generated with program pymol education edition.  
7  
 
 
The two types of heme for which we studied the rate of heme transfer are proto-
heme which is native and the meso-heme, which differs on the side chains (R1) as 
shown below (21) in Fig.1.5. 
 
Fig.1.5. Structure of Fe-proto and mesoporphyrin IX . 
 
Human GAPDH has a total of 3 cysteines at positions 152, 156 and 247, rabbit 
GAPDH has total of 4 cysteines at 150, 154, 245 and 282 respectively. Previous 
work from our lab suggests that heme insertion is regulated by NO via specific 
nitrosylation of GAPDH in vivo. This project explores an in vitro model to 
identify which cysteine is involved in nitrosylation. In addition, we investigate 
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whether a correlation exists between the nitrosylation of specific cysteine and the 
rate of heme transfer to apomyoglobin. We determined the extent of nitrosylation 
 of each specific cysteine on GAPDH by mass spectrometry. 
 
1.3 Nitrosylation: 
Nitrosylation of proteins is becoming an important physiological process involved 
in major role in host defense, neurotransmission and DNA repair.  The transfer of 
NO group (nitric oxide) from NO donor to free SH group which are present on 
proteins leading in formation of nitrosothiols (RSNO) is known as nitrosylation of 
proteins (22). Thiol groups play an important role in quaternary structure and co-
factor binding. Free SH group is a good biological nucleophile and is good targets 
for electrophiles and also for redox agents which includes nitrosylating and 
oxidizing species generated from NO. S-nitrosylation influences protein function 
such as enzyme inhibition by blocking active site which is Cys 152. The cysteines 
are the main targets for nitrosylation. In general RSNO bond is unstable and hence 
it is difficult to quantify (23). 
The physiological RSNO’s includes S-nitrosoglutathione (GSNO) and S-nitroso-
L-cysteine which have been detected and quantified in vivo (24). Protein S-
nitrosylation has inhibitory effects on blood clot formation and it is demonstrated 
that factor XIII is target for S-nitrosylation on a highly reactive cysteine residue 
which has inhibitory effect on blood coagulation and so RSNO’s plays a major 
role in hematology (25). S-nitrosylation of GAPDH prevents cytotoxicity by 
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binding with the novel protein GOSPEL (26). Nitrosylation is specific which 
means that every free SH group is not nitrosylated and if nitrosylated, nitrosylation 
may not be to same extent (27). In our target protein human GAPDH we have 3 
cysteines in total at positions 152, 156, and 247 in the primary structure. As per 
the results of mass spectrometry we observed that extent of S-nitrosylation varies 
on each cysteine. S-nitrosylation inactivates GAPDH, and is reversible as S-
nitrosylated GAPDH is unstable as SNO bond is liable (28).  
 
Biotin switch technique: 
S-nitrosylation of proteins is continuously emerging as physiologically important 
modification by which many cell functions are monitored. It is important to 
determine which free SH group undergoes nitrosylation and also to determine the 
extent of nitrosylation on each individual free SH group. The principle in biotin 
switch includes blocking of free SH groups by using thiol blocking agents like 
MMTS (methyl methane thiosulfonate) or NEM (N-ethylmaleimide) after 
nitrosylation so that only Nitrosylated cysteines are available for biotin in next 
step. The next step is reducing the S-Nitrosylated thiol with ascorbate and finally 
the reduced form is labeled with Biotin-HPDP. The amount of nitrosylation which 
is in terms of biotinylation can be determined by either immunoblotting or by 
using mass spectrometry (29, 30).     
Modified biotin switch method: This is a slight modification of biotin switch 
technique. This has high sensitivity in quantitative estimation of nitrosylation on 
10 
 
 
each individual free thiol group in a protein. Here we replace normal thiol blocker 
MMTS with NEM and iodoacetamide for alkylating nitrosylated cysteines instead 
of biotin-HPDP.  
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CHAPTER II 
 
EXPERIMENTAL METHODS 
 
2.1 Preparation of heme solution: 
The heme solution was prepared by dissolving 10 mg hemin ( MP biomedical pdt 
# 02198820) in 4.5 ml water, add little 1 M NaOH (Fisher Scientific# s318-1 CAS 
1310-73-2), until visually dissolved. Spectra were collected from 700-300nm 
using a Schimadzu UV-VIS spectrophotometer, NaOH was added until 
consecutive peaks at 385 nm remain unchanged. Then filter the heme solution 
through 0.22 micron filter and collect the filtrate. The concentration of heme was 
measured by the heme-chromogen assay. 
The heme-chromogen assay was performed using Schimadzu UV-VIS 
spectrophotometer. The heme-chromogen reagent was prepared by mixing 400 μl 
pyridine, 400 μl water and, 1M 200 μl NaOH. 5 μl heme solution (dilution 
depends on concentration of heme solution) was added to 495 μl heme chromagen 
reagent, mix with dithionite and incubate for 2-5 minutes. The baseline was taken 
with heme chromagen reagent in the cuvette. Spectra were collected from 700-400 
12 
 
 
nm. The peak height at 556 nm was measured, using extinction coefficient of 
34600/ M CM (31).  
 
2.2 Preparation of GAPDH-heme complex: 
2mg GAPDH from rabbit muscle (sigma PDT# G2267) was dissolved in Hepes 
(Fisher Scientific# BP 310-500 CAS 7365-45-9) 50mm/100mm NaCl (NPI CAS# 
7647-14-5 >99% pure)/pH 7.4, to achieve a final concentration of 200 μM. Then 
the protein solution was incubated with 300 μm heme for 30-45 min at room 
temperature. Disposable PD-10 desalting columns (GE health care PDT Code# 17-
085-01), which were pre packed with sephadex G-25 medium. These were used to 
remove unbound small molecules from large molecules like proteins. These PD-10 
columns were washed with 5-7 column washes water and equilibrated with 50mm 
HEPES/ 100mm NaCl/ pH 7.4. The GAPDH-Heme complex was then passed 
through these PD-10 columns. This Pd-10 gel filtration step removes free heme 
from protein-heme complex. The fractions each of 500 μl were collected in 1.5 ml 
centrifugal tubes and protein concentration of fractions was determined, fraction 
containing GAPDH-heme complex was used for further analysis. 
 
2.3 Estimation of Protein concentration: 
The concentration of protein was determined by taking spectral scan from 700-250 
nm and by measuring peak height at 280 nm using UV-VIS spectrophotometer. 
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The extinction coefficient used for GAPDH was 30000/ M CM. The extinction 
coefficient used for apomyoglobin was 15200/M CM. 
 
2.4 Koff or transfer of heme from GAPDH from GAPDH-heme complex to 
apomyoglobin: 
We established an in vitro system to study the transfer of heme from GAPDH-
heme complex to apomyoglobin. Multiskan spectrophotometer was used to 
measure transfer rates that can read 96wells at same time, this is used to conserve 
time and material. The principle involved here, is to monitor the spectral changes 
that occur upon heme transfer from GAPDH-heme complex to apomyoglobin. 
Spectral changes recorded for 90 minutes with 30 second interval, heme transfer 
from GAPDH-heme complex to apomyoglobin is irreversible. 20 μM GAPDH of 
200 μL was taken into each well and surrounding wells were filled with water to 
prevent evaporation, 40 μM apomyoglobin was added into 3 sample wells, no Apo 
myoglobin into control wells. Spectral changes at 398 nm and 700 nm was 
recorded for Fe-mesoporphyrin IX and 411 nm and 700 nm for Fe-protoporphyrin 
IX. Subtracting 398 nm from 700nm and sample from control wells for Fe-
mesoporphyrin IX, and 411 nm from 700 nm and sample from control for Fe-
protoporphyrin IX, rates of heme transfer were calculated by fitting to exponential. 
Hsp90 and cell lysate proteins effect on the rate of heme transfer to apomyoglobin. 
The compositions of different mixtures for each reaction well are listed below. 
 GAPDH human-proto heme Complex concentration into each well           =10 μM. 
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Apomyoglobin concentration into each well                                                =20 μM. 
Cell lysate mix into each well                                                              = 4.95 mg/ml. 
Cell lysate 50k and more into each well                                              = 4.45 mg/ml. 
Cell lysate 50k and more into each well                                             = undetectable. 
Hsp90 alpha into each well                                                                  = 2.52 μM. 
Hsp90 beta into each well                                                                    = 12.52 μM. 
ATP into each well                                                                               = 1.6 mM.  
 
2.5 GAPDH activity: 
GAPDH activity was determined by measuring the changes in absorbance at 340 
nm which is the absorbance for NADH. Assay mixture for activity contains 82.3 
mM triethanol amine (Sigma# T9534-250g 99.5 % pure) buffer pH 7.6, 1.1 mM 
ATP (Sigma# A2383-10 g), 6.2 mm glycerate 3-phosphate (Sigma# P8877-1g 99 
% pure), 0.2 mM NADH (Sigma# N-8129 98% pure), 0.9 mM EDTA (Sigma# 
E5134-1 kg), 2 mM MgSO4 (Sigma# M7774) and phosphoglycerate kinase (13 
units/ml) (Sigma# P7634-2 ku) (14). 
Kinetics of NADH disappearance was measured by using Schimadzu UV-VIS 
spectrophotometer at 340 nm. 0.1-0.5 μM of GAPDH was taken into the cuvette 
containing 495 μl of activity mixture and the activity was calculated by measuring 
the rate of change of absorbance per minute at 340 nm, where NADH is oxidized 
into NAD. 1 unit of GAPDH oxidizes 1 mole of NADH. Enzymatic activity was 
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calculated from the slope and by using extinction coefficient 6.22/ M CM (NADH 
at 340 nm).  
 
2.6 Preparation of CYS-NO: 
CYS-NO was prepared by taking 200 mM L-cysteine (Aldrich# 168149-25 g 97 % 
pure) in 200 μM DTPA (Fluka# 32319-100 g-F.) and 200 mM HCl of 500 μl 
mixed with 500 μl sodium nitrite (Sigma#s-2252-500 g) solution of 210 mM. The 
solutions were mixed and incubated in the dark for 10 minutes. The pH was 
adjusted to 8 with NaOH. The concentration was measured at wavelength 336 nm 
by Shimadzu UV-VIS spectrophotometer by using an extinction coefficient of 900 
/M CM. 
  
2.7 Preparation of SNO-GAPDH:  
500 μl of 100 μM of recombinant human GAPDH were made in 50mM HEPES, 
100 mM NaCl, 75 μM DTPA, pH 7.4. 50 fold CYS-NO was added and incubated 
for 30 minutes. Passed it through PD-10 columns made of G25 resin and fractions 
were collected and the protein concentration was determined by measuring the 
absorbance at 280 nm on a Shimadzu UV-VIS spectrophotometer by using 
extinction coefficient 30000 /M CM. 
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PD-10 G25 gel filtration
Collect fractions
Control
-Hgcl2 
 
Total SNO= Absorbance of sample  
                    at 540nm 
 -
Saville's method 
Incubation in the dark for 30 minutes 
at room temperature 
GAPDH (100uM) + Hepes 
buffer (50 mM, pH 8.0) + 
Cys-No (5000uM) 
 
Fig.2.1. Schematic representation of the method to generate nitrosylated GAPDH and its 
quantification. 
 
2.8 Saville’s method: 
A colorimetric assay was used for the quantification of SNO. HgCl2 displaces NO 
and the NO was made to react with Griess reagent. Griess reagent includes 3.4% 
W/V sulfanilamide (Sigma# S-9251.) in 0.4 M HCl and 0.1%W/V of N-(1-
naphthyl) ethylenediamine (NED) (Sigma# N-9125.). HgCl2 (Sigma# M-6529) 
was mixed into sample and not into control. The difference between HgCl2 
absorbance reading and without HgCl2 absorbance reading gives the amount of 
SNO. The absorbance was measured at 540 nm. The exact procedure includes 100 
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μl of nitrosylated protein sample and 50 μl 3.4% W/V sulfanilamide with HgCl2 
10 mM and 50 μl 0.1% W/V of N-(1-naphthyl) ethylenediamine (NED) and 
control includes the same without 10 mm HgCl2. The detection limit was 500 nM.  
A summary of this method was provided in Fig.2.1. 
The standard curve was made by using nitrite solution of different concentration 1 
μm, 2.5 μm, 5 μm, 7.5 μm, 10 μm, 12.5 μm, 15 μm, 20 μm, 25 μm, 50 μm, 75 μm, 
100 μm. The slope was calculated and by using slope, amount of SNO on protein 
was calculated from the absorbance at 540 nm.  
 
2.9 Treatment of the protein with DTT: 
To reduce disulphide bonds the protein was incubated with DTT (Dithiothreitol).  
In our studies for nitrosylation of proteins essentially there should not be any 
disulphide bonds. We treat proteins with 10 fold excess of DTT for 1.5-2 hours 
and the excess DTT is removed by passing it through PD-10 column which are 
previously washed and equilibrated with buffer (32). 
 
2.10 Effect of pH and oxygen on nitrosylation: 
Degassing of buffers and reagents:  
All the buffers, NaOH, DTPA solutions were degassed by using nitrogen gas for 2 
hours. 
Placing the materials inside Anaerobic Chamber: 
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PD-10 columns, L-Cysteine, sodium nitrite, DTPA/HCL solution, Rabbit GAPDH 
lyophilized powder, Human C152S mutant GAPDH, 1M NaOH, HEPES 50mM/ 
100 mM NaCl/75 μm DTPA buffers with pH 6, 7, 8. Griess reagent, HgCl2, 1.5 ml 
centrifugal tubes, cuvettes, 96 well plates, water were placed in vacuum port for 
degassing by using nitrogen gas and then in anaerobic chamber. The Cys-NO and 
SNO-GAPDH was made in anaerobic chamber. 
Note: Everything has to be done in the dark as SNO bond is light sensitive and 
liable by light. 
 
2.11 Preparation of GAPDH at different pH: 
A solution of 100 μm Human C152S GAPDH and Rabbit wild type GAPDH were 
made in 50 mM HEPES, 100 mM NACL, 75 μM DTPA in 3 different pH ranges 
6, 7, and 8 by measuring concentration at wavelength 280 nm by Shimadzu UV-
VIS spectrophotometer by extinction coefficient 30000/M cm.  
 
2.12 Site directed mutagenesis: 
Cysteines in GAPDH were replaced with serines to identify site of nitrosylation 
and its effect on heme binding and heme delivery. There are a total of 3 cysteines 
in human GAPDH at 152,156 and 247 and total of 4 cysteines in rabbit GAPDH at 
150, 154, 245 and 282 positions. The mutations which were considered were 
single mutations C152S, C247S and double mutations C152/156S, C152/247S, 
C156/247S and a triple mutant C152/156/247S in which all the cysteines were 
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replaced with serines. We consider serine as replacement because serine has near 
equal molecular size as cysteine. The required DNA sequencing primers were 
obtained from IDT.  
 
2.13 Polymerase chain reaction:  
This is a molecular biology technique which is used for the amplification of DNA 
to generate millions of copies of particular DNA sequence.  It involves repeated 
cycles of heating and cooling for DNA melting and DNA replication. The 2 
complementary oligonucleotides which have the desired sequence or mutation 
were obtained from IDT. The PCR mixture has the following 5 μl of 10X reaction 
buffer, 10-20 ng ds DNA template, 125 ng of oligonucleotide primer 1, 125 ng of 
oligonucleotide primer 2, 1 μl dNTP mix and make into 50 μl with ddH2O. 1μl of 
pfu turbo DNA polymerase (2.5 U/ μl) was added. The dNTPs were the building 
blocks from which new DNA strand is synthesized by DNA polymerase. The 
quick change XL site directed mutagenesis kit was obtained from Stratagene 
(Stratagene# 200517-5). 
The robocycler for PCR was set up by using following the program a.) Segment 1 
has 1 cycle at 950 C for 30 seconds. b.) Segment 2 has 18cycles each at 950 C for 
30 seconds, 550 C for 1 minute and 680 C for 10 minutes. Segment 3 has 0 cycles 
and every temperature for 0 seconds. Segment 4 has 60 C, set up for overnight, and 
after reaction was done, it stays at 60 C. DPN1 was added finally to PCR mixture 
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and incubated at 370 C for 2 hours to degrade template DNA, the PCR mixture 
was transformed into XL 10 Gold ultra competent cells.  
 
2.14 Transformation into XL10-Gold ultra competent cells: 
The XL10 Gold ultra competent cells (Cat# 200315) were obtained from 
stratagene. Two 14 ml BD falcon tubes were chilled on ice and NZY broth was 
heated to 420 C. The XL-10 cells were thawed on ice and 50 μl of cells placed in 
each of the tubes and add 4 μl 2ME, swirl every 2 minutes for 10 minutes by 
placing on ice. 2 μl of PCR mixture was added and incubated on ice for 30 
minutes, Heated in water bath at 420 C, incubated on ice for 2 minutes. 0.5 ml 
preheated NZY broth was added to the mixture and incubated at 370 C for 1 hour 
shaking at 250 rpm. 250 μl of cells were plated on pre warmed LB-Amp agar 
plates and incubate overnight at 370 C. The colonies were sequenced to confirm 
the presence of mutation. 
 
2.15 DNA purification: 
Up to 6 colonies were picked from each plate and grown in LB-Amp overnight. 
The cells were harvested in 6 different centrifugal tubes by spinning down at 
13000 rpm for 2-3 minutes and the supernatant was discarded. Cells were 
suspended in 250 μl P1 buffer to which RNase was added previously. 250 μl P2 
buffer was added and mixed, 350 μl N3 buffer which is neutralization buffer was 
added and mixed. Centrifuged for 10 minutes at 13000 rpm and supernatant was 
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applied to QIA prep spin column and flow through was discarded as our plasmid 
DNA was bound to column. Washed with 0.75 ml washing PE buffer and 
centrifuged for 60 seconds. Flow through was discarded and centrifuged for 1 
minute to remove any remaining PE buffer. The last step was the elution of the 
DNA. Clean autoclaved 1.5 ml centrifugal tubes were taken and QIA prep column 
(Qiagen# 27106) was placed into them, 50 μl elution buffer was added to column 
and centrifuged for 1 minute. The plasmid DNA was eluted into centrifugal tube.  
 
2.16 Transforming DNA into over expressing cells: 
The plasmid DNA carrying the desired mutation was transformed into over 
expressing BL-21 cells. 1.5 ml C-medium was heated to 370 C and 0.15 ml of 
overnight culture was added to 1.5 ml C-medium which was at 370 C and left in 
shaker for 20 minutes at 370 C. Transform aid T-solution was prepared by mixing  
250 μl  of T-solution (A) and 250 μl T-solution (B) (Fermentas# K2711). The 
culture (C-medium) was spun down at 13000 rpm for 2 minutes and the pellet was 
suspended in 300 μl transform aid T-solution, incubated on ice for 5 minutes. 
Centrifuged, supernatant was removed and 120 μl transform aid T-solution was 
added and incubated on ice for 5 minutes. 1 μl DNA was added into 50 μl cells in 
transform aid T-solution and incubated on ice for 5 minutes. Cells were plated on 
LB-Amp agar plates which were pre warmed at 370 C and incubated overnight at 
370 C, control was performed by plating 50 μl cells from transform aid T-solution 
without adding plasmid DNA on to LB-Amp agar plates, colonies were picked 
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from the LB-Amp agar (no colonies on control.) and were grown in LB-Amp. 
Stocks were made by using 500 μl 50% sterilized glycerol and 500 μl culture and 
were stored at -800 C.  
 
2.17 Checking the protein expression of different mutants of GAPDH:  
To check the protein expression, 3 individual colonies from each mutant GAPDH 
LB-Amp agar plate were selected and grown in 20 ml LB-Amp for 12-16 hours. 
The cells were pelleted by spinning at 5000 rpm at 40 C for 10-15 minutes. For 
each 100 mg pellet 200 μl B-PER (bacterial protein extraction reagent) (PDT# 
90084 thermo scientific) was added, cells were pipetted with B-PER until it is 
homogeneous, incubated for 15-20 minutes at 40 C. Centrifuged at 15000 rpm for 
5 minutes, our protein of interest is cytosolic protein and hence remains in 
supernatant. Supernatant was incubated with GST beads for 2 hours, GST beads 
(Pharmacia biotech# 17-0756-01) were washed with 1XPBS to remove unbound 
proteins which does not have GST, GST with GAPDH remains with the GST 
beads. The GST beads were then eluted with GSH (Sigma#G-4251) containing 
buffer and now GST with GAPDH was present in Buffer.   Protein concentration 
was determined for this protein in buffer. The colony which expresses maximum 
protein of our interest is further used for purification in larger batches. Protein 
expression was determined by western blotting by using Anti-GST, since GAPDH 
which we use has a GST tag, so the band shows at around 60 KDa. Depending on 
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the intensity of the signal, colony that expresses optimum levels of protein of 
interest was selected.  
 
2.18 Purification of myoglobin mutant: 
Myoglobin mutant from sperm whale myoglobin was purified from a stock culture 
of E.coli strain ER2566 (NEB) and plasmid with pUC19 vector. 100 ml LB with 
125 μg/ml ampicillin was inoculated with stock culture, grown overnight at 370 C, 
shaking at 250 rpm. 4 liters terrific broth with 125 μg/ml ampicillin was divided 
into 8 flasks and into each flask 10 ml of overnight culture is inoculated and 
shaken at 370 C for 1.5-2 hours and once stationary phase is reached which is 
measured at 600 nm by using spectrophotometer optical density should be around 
0.8 to 1, the cells were spin down at 6500 rpm for 20 minutes at 40 C. The pellets 
if not used immediately were kept frozen at -800 C till use. The cell pellets were 
thawed and resuspended in 100ml lysis buffer which was made of 50 mM Tris 
HCl pH 8.0, 1 mM EDTA, 0.5 mM DTT, 0.5 mM DTT, 5 unit/ml DNase, 1 mg/ml 
lysozyme, PI#1 (5 mg/ml Aprotinin, 1 mg/ml Leupetin), PI#2 (1 mg/ml Pepstain 
A, 24 mg/ml Pefabloc SC in DMSO) and 1 μM PMSF and left on ice for 30 
minutes. The cell suspension was sonicated at 36% amplitude for 35 seconds for 3 
times. The sonicated cell suspension was centrifuged at 20000 rpm for 45 minutes 
at 40 C to remove cell debris. The supernatant was brought to 60% ammonium 
sulfate saturation slowly; after 60% saturation was reached the solution was 
allowed to sit at 40 C for 2 hours. The 60% saturated solution was centrifuged at 
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20000rpm for 30 minutes to remove precipitate, supernatant was then made to 
saturate with ammonium sulfate till 95%. The precipitate was collected by 
centrifugation at 20000 rpm at 40 C for 30 minutes, stored at -800 C till use. The 
precipitate from ammonium sulfate precipitation was resuspended in 30 ml 50 mM 
Tris HCl pH 8.0, 2 M Ammonium Sulfate and centrifuged again at 20000 rpm for 
30 minutes at 40 C to remove any pellet, supernatant was loaded onto phenyl 
sepharose column which was previously equilibrated with 50 mM Tris HCl pH 
8.0, 2 M Ammonium Sulfate. Column was equilibrated with 3-4 column washes of 
50 mM Tris HCl pH 8.0, 2 M Ammonium Sulfate. Elute myoglobin with 2 column 
volumes of 20:80 ratio of 50 mM Tris HCl pH 8.0, 2 M Ammonium Sulfate (20): 
50 mM Tris HCl pH 8.0 (80). Collected fractions were dialyzed against 50 mM 
Tris HCl pH 8.0 with 1 buffer change. Dialyzed sample was passed through the 
DE-52 column which was equilibrated with 50 mM Tris HCl pH 8.0 and the flow 
through was collected. Myoglobin was concentrated to 1mM (17).  
0.3 ml of the concentrated myoglobin solution was placed in 2-3 microcentrifuge 
tubes and place on ice. 100-300 μl of 0.1 M HCl was added to adjust pH to 2.3-
2.5, 0.4 ml cold methyl ethyl ketone was immediately added to each of the tubes 
and the solution was left on ice for 1 minute and centrifuged for 2 minutes to 
separate 2 phases. The organic phase was removed and the process was done until 
there was no visible heme. The aliquots were combined and dialyzed against cold 
water for 4 to 6 hours and repeated for 3 to 4 times. The samples were lyophilized 
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and stored at -800 C. The samples were reconstituted with buffer and concentration 
was measured at 280nm by using extinction coefficient 15200 /M CM. 
 
2.19 Purification of GAPDH: 
500 ml of LB was inoculated with glycerol stock of GAPDH and 1 ul/ml of 
ampicillin was added, incubated at 370 C with shaking at 250 rpm for 14 to 16 
hours. 50 ml of grown culture was transferred into 500 ml TB with 1ul/ml 
ampicillin and incubated at 370 C with shaking at 250 rpm until optical density 
reaches 0.8 to 1. The cultures were induced with 1 mm IPTG and the cultures were 
left shaking at 250 rpm for 48 hours at room temperature. Cells were spun down at 
7000 rpm at 40 C for 30 minutes. Supernatant was discarded and the cell pellets 
were stored at -800 C until used. Lysis buffer was prepared using 100 ml PBS, 0.5 
mm EDTA, 1 mg/ml lysozyme, 1 mm PMSF/DMSO, PI#1, PI#2. Pellet was 
thawed using 10 to 13 ml lysis buffer and gently suspended. Suspension was 
sonicated for 35 seconds at 36% amplitude by altered pulses for 7 seconds. This 
step was repeated for 3 to 4 times until the suspension become thinner and darker. 
The suspension was centrifuged at 18,000 rpm for 1 hour and the supernatant was 
collected, incubated with GST sepharose resin for 2 hours at 40 C. The GST 
sepharose resin was prepared by washing and equilibrating with 1XPBS. GST 
sepharose resin was spun down at 600 rpm for 3 minutes at 40 C and thick 
supernatant was discarded, as the desired protein was bound attached to GST 
sepharose resin. This step was repeated by adding 1XPBS and for 2 to 3 times, and 
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PBS with resin was added to column. For elution, buffer with 100 mm Tris-HCL 
pH 8, 10 mm GSH was prepared. Elution buffer was added to the column having 
the GST resin and agitated for 1-2 minutes and the flow through was collected. 
This step was repeated for 2 to 3 times to collect all the GST bound protein. The 
collected protein was concentrated using Amicon 30 K concentrator to 2-3 ml and 
washed with 1XPBS with 3 mm DTT and concentrated to 2 to 3 ml again. 
Thrombin (10 unit/mg 50 ul) was added to this concentrated protein which cleaves 
the GST tag from protein, incubated at 370 C for 2 hours, the protein with 
thrombin was incubated with GST resin at 40 C for 2 hours to remove any protein 
which has GST tag, flow through was collected. The protein was then passed 
through Benzamidine FF resin (GE heath care#17-5123-10) which has been 
previously equilibrated with 50 mm Tris HCl and 500 mm NaCl, pH 8 to remove 
excess thrombin. The protein was concentrated to 2 to 3 ml by using Amicon 30 K 
concentrator, washed with 50 mm Tris pH 8 150 mm NaCl, 20% glycerol (Fisher 
bio reagents# BP229-4) for 2 to 3 times and was concentrated to 2 to 3 ml. To 
determine the purity SDS-PAGE was performed, our desired protein (GAPDH) 
has molecular weight of 37 KDa approximately (11).  
 
2.20 SDS-PAGE:  
SDS-PAGE was used to separate proteins by their molecular weight. The lower 
gel (separating gel) was made by using 5.6 ml 30% acrylamide (National 
diagnostics# EC-890), 5 ml 1.5 M Tris (Sigma# T1503-1 kg 99.9% pure), pH 8.8 
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with SDS (CAL Biochem# 428015), 9.1 ml water, 100 μl of 10% APS 
(Amresco#K833-100tabs), TEMED (Sigma# T9281-50ml) 20 μl, which indicates 
the separating gel is a 8.5%. The upper gel (stacking gel) was prepared using 1.3 
ml 30% acrylamide, 2.5 ml 0.5 M Tris pH 6.8 with SDS, 6.1 ml water, 50 μl 10% 
APS, 20 μl TEMED. Samples were mixed with sample buffer which consists of 
glycerol, SDS, 2-mercaptoethanol (Sigma# M-3148), bromophenol blue and 
water, boiled for 5 minutes at 950 C and were cooled down to room temperature. 
The protein samples were then loaded onto the gel. Non- reducing sample buffer 
which has no 2-mercaptoethanol was used for mass spectrometry experiments, 
where the protein samples were reduced during mass spectrometry sample 
digestion. The gel electrophoresis was performed at 90-100 V. Once the 
electrophoresis was finished, the gel was removed and stained with coomassie 
blue for 1 hour and destained using 30% methanol and 7% acetic acid overnight. 
The protein was identified by the blue bands and the molecular weight was 
determined using commercially available standards (Precision blue protein marker 
from Bio-Rad# 161-0373).  
 
2.21 Western blotting technique: 
It is a widely used technique to detect the specific protein or the protein of interest. 
This is also known as immunoblotting as it uses specific antibodies to detect the 
specific protein. After the gel electrophoresis was done, gel was washed with 
water for 10 minutes and equilibrated with semidry transfer buffer. The PVDF 
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membrane of size of gel was cut and activated with methanol, blotting sheet was 
equilibrated with semidry transfer buffer. The equilibrated blotting sheet was 
placed on transfer apparatus and then PVDF membrane, followed by gel and 
finally with one more equilibrated blotting sheet. Air bubbles should be avoided. 
Transfer was done for 40 minutes at 6 amperes current. The proteins were then 
transferred onto PVDF membrane. The blocking of PVDF membrane was done by 
using 5% non fat dry milk in PBS mixed with tween 20 overnight. The blocked 
PVDF membrane was incubated with primary antibody which was made by 
diluting antibody in 5% non fat milk for an hour at room temperature. The PVDF 
membrane was then washed with PBST for 3 times and incubated with secondary 
antibody for 1hour and then washed with PBST for 3 times and finally washed 
with PBS before adding substrate. ECL kit which is enhanced chemiluminescence 
was used for detecting secondary antibody which in turn gives signal about 
primary antibody and the primary antibody is specific for each protein. The 
detection solutions A and B were mixed in ratio of 40:1 on PVDF membrane after 
secondary antibody and washing steps, incubated for 5 minutes and after 5 
minutes excess detection reagent was drained out and the PVDF membrane was 
placed on a cassette by placing it inside a wrap and the interface should be black. 
Expose Kodak scientific imaging film on the wrapped PVDF membrane in the 
dark. Film was developed. The signal was seen as dark band. The intensity of the 
signal is proportional to the amount of protein in the original sample. In biotin 
switch technique only one antibody was used which is biotin antibody which is 
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HRP conjugated and directly interacts with biotin. Here after blocking with milk 
wash PVDF with PBST and then finally with PBS followed by incubation with 
biotin antibody for 1.5 to 2 hours. Then ECL technique was used as previously 
described and Kodak scientific imaging film is used to detect the 
chemiluminescence signal which is due to substrate bound to HRP conjugated 
antibody which in turn indicates the specific protein. 
 
 
 
with ECL 
ECL Reaction with ECL 
Fig.2.2. Schematic representation of Western blot technique. 
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2.22 Estimation of the extent of nitrosylation by SNOB reagent using western 
blot: 
Stock concentration of 10.6 mm was prepared by dissolving 1.5 mg of SNOB 
reagent (Tocris# 3879) and SNOB control (Tocris# 3880) in 50 μl of DMSO, then 
dissolved in 500 μl PBS, stored at -200 C. The stocks were stable for a month in 
the dark at -200 C. Nitrosylation of the protein was carried out as previously 
described. 50 μm of nitrosylated and non nitrosylated GAPDH was treated with 20 
fold excess of SNOB reagent and control for 30 minutes at 600 C or 2-3 minutes 
exposing to high intensity light and excess SNOB was removed by passing 
through the PD-10 columns. The concentration of protein was determined and the 
same amount of protein was loaded into the gel with non-reducing sample buffer 
and gel electrophoresis was performed. After the gel was done the electrophoresed 
proteins were transferred onto PVDF membrane and immunoblotted using a biotin 
antibody. Mechanism of working of SNOB reagent was represented below.  
 
Fig.2.3. Reaction of the SNOB reagent with nitrosylated protein. 
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2.23 Sample preparation for mass spectrometry to determine the extent of 
nitrosylation on each individual cysteine: 
Human and rabbit GAPDH were nitrosylated as previously described. 50 μm of 
200 μl GAPDH were taken and 50 mm of 400 μl of NEM was added, incubated at 
room temperature for 1.5 to 2 hours. Excess NEM (Thermo scientific# 23030) was 
removed by acetone precipitations which was done by adding 20 volumes pre-
chilled acetone to protein and incubated at -200 C for 20 minutes, centrifuged at 
minimum of 2000 rpm for 10 minutes, precipitate was dissolved in 100 μl Hepes 
buffer with 1% SDS. 4 mM of 300 μl biotin HPDP (Pierce net# 21341) and 50 
mM ascorbate solution was added to this dissolved protein. The samples were then 
mixed with non-reducing sample buffer and loaded onto gel and gel 
electrophoresis was performed. The staining was done using the gel code blue 
reagent, for overnight and then samples were subjected for mass spectrometric 
analysis.  
Biotin HPDP was replaced with alkylating agent iodoacetamide (Acros organics# 
AC12227-0050), since we got very less biotinylation, when compared to 
nitrosylation with Saville’s method. In iodoacetamide method after acetone 
precipitation, protein was dissolved in HENS buffer and 10 mm DTT for 100 μm 
protein, incubated for 2 to 3 hours. Iodoacetamide was added in excess which is 4 
to 5 fold excess of DTT as DTT reacts with iodo acetamide and incubated for 2 
hours. Proteins were mixed with sample buffer which is non-reducing with no 
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boiling and loaded onto gel and gel electrophoresis was performed. The gel was 
stained with gel code blue (Thermo#24592) and subjected to mass spectrometry. 
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CHAPTER III 
RESULTS AND DISCUSSION 
 
3.1 Characterization of Heme transfer reactions using GAPDH-heme to 
apomyoglobin as a model:   
My project focuses on kinetics of heme dissociation from the GAPDH-heme 
complex which is measured by the rate of heme binding to apomyoglobin. This 
was measured by the absorbance changes occurring at 410nm with time for proto-
heme and at 398nm for meso-heme.  
The typical spectrum of the GAPDH-heme complex looks like below after passing 
the GAPDH-heme complex through PD-10 columns where free heme was 
removed and only heme bound to GAPDH was eluted. Typical ratio of heme 
bound to GAPDH is 0.5 heme to 1 monomer GAPDH.     
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Fig.3.1. UV-Vis spectrum of heme bound GAPDH. The near 400nm peak represents heme bound 
to GAPDH peak and the wavelength maximum at 280nm represents GAPDH peak.                             
 
A typical time course for the transfer of heme from GAPDH to apomyoglobin was 
shown in Fig.3. 2. The rate difference was monitored by spectral changes against 
time.  
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Fig.3.2.1 Typical curve for meso heme transfer from GAPDH-heme complex to apomyoglobin. 
The monitored wavelength is 398nm for meso-heme.   
 
Fig.3.2.2 Typical curve for proto heme transfer from GAPDH-heme complex to apomyoglobin. 
The monitored wavelength is 411nm for proto-heme  
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The rates of heme transfer were different for 2 heme types which were considered 
here. The 2 types of heme which are considered here are meso and proto heme. 
The rate of heme delivery was 2 times faster for meso heme compared to that of 
proto heme which is shown in the Fig.3.3. Meso heme differs from proto heme in 
the side chain. 
      
 
Fig.3.3. In the above graph red column represents meso heme which shows that it has faster rate 
of heme delivery compared to that of proto heme which is represented by black column. 
 
The rate of heme transfer from GAPDH-meso heme complex is faster to 
apomyoglobin, compared to the rate of heme transfer from GAPDH-proto heme 
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complex. The reason may be that, meso heme is less strongly bound to GAPDH, 
when compared to binding of proto heme to GAPDH. 
We focused on factors affecting the rate of heme transfer.  
Effect of GAPDH-Heme complex concentration on rate of heme transfer to 
apomyoglobin: 
We examined if GAPDH-heme complex concentration has any effect on heme 
uptake by apomyoglobin by maintaining same ratio of complex to apomyoglobin 
ratio. GAPDH-heme complex was used in different concentrations in each well 
and apomyoglobin added was 3 fold excess to that of heme concentration. 
Changing the concentration of complex has no effect on rate of heme transfer to 
apomyoglobin, as shown in Fig.3.4. 
 
Fig.3.4. Comparing different amount of GAPDH-heme complex to same fold of apomyoglobin. 
As the results show it has no substantial effect on rate of heme transfer.     
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Effect of heme: GAPDH ratio on the rate of heme transfer to apomyoglobin: 
We examined if the amount of heme bound to GAPDH influences the rate of heme 
transfer to apomyoglobin. GAPDH-heme complexes were prepared considering 
100uM GAPDH as constant and increasing heme concentrations from 100uM, 
200uM, 400uM, 800uM and passed them through PD-10 gel filtration columns to 
remove free heme. Same protein concentration, different heme concentration and 
maintained same apomyoglobin: heme ratio was maintained in each well. The 
results from this experiment suggest that the rate of heme uptake by apomyoglobin 
is independent of amount of heme bound to GAPDH.  
 
Fig.3.5. Comparison of rates of heme transfer when different amount of Heme placed into each 
well maintaining GAPDH same. The results show that there was not much substantial difference 
in rate of heme transfer.   
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3 complexes were made with same GAPDH concentration and with different heme 
concentrations. Same amount of heme and apomyoglobin were loaded into each 
individual well. Here the variable was GAPDH. The effect seems to be increasing 
as GAPDH is decreasing but it’s less than 20% which is with in the experimental 
error range. 
 Amount ofAmount of GAPDH
20 µM 12.5 µM10 µM 
Fig.3.6. Comparison of rate of heme transfer when different amount of GAPDH is placed into 
well by maintaining same amount of heme into final well. The result shows that the effect is not 
substantial, although it shows that rate is increasing with lowering amount of GAPDH.  
 
Effect of NO on the rate of heme transfer from GAPDH to apomyoglobin: 
We examined if any external factors has an affect on rate of heme uptake by 
apomyoglobin. We here focused on NO as it has many physiological roles, since 
specific nitrosylation of GAPDH at cysteine 152 was shown to block cellular 
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heme insertion into iNOS (9). The first experiment which was considered was 
adding NO donor GSNO to GAPDH-heme complex incubating less than 5 
minutes before adding apomyoglobin. As shown below here there is no substantial 
effect of NO on rate of heme delivery. 
. 
 
Fig.3.7. Comparison of rate of heme transfer from GAPDH-heme complex to that of GAPDH-
heme complex with nitrosylation donor added to it before adding apomyoglobin. . The result 
shows that S-nitrosylation of GAPDH has no effect on the rate of heme transfer. 
 
Effect of Hsp90 and cell lysate proteins on rate of heme transfer from GAPDH-
heme complex to apomyoglobin:  
We examined if Hsp90 has an affect on rate of heme transfer, which is a 
chaperone and is believed to have an involvement in heme insertion into a number 
41 
 
 
of proteins (8). Cell lysate fractions of human macrophages were prepared, rate of 
heme transfer to apomyoglobin from GAPDH-heme complex were compared to 
that of GAPDH-heme complex mixed with macrophage cell lysate and Hsp90. 
The results suggest that Hsp90, cell lysate proteins does not affect the rate of heme 
transfer. We maintained same GAPDH-heme complex to apomyoglobin ratio.  
contents value 1 value 2 average 
a.)  Apomyoglobin+ complex 8.999x 10-4 1.02x 10-3 9.599x10-4 
b.)  Apo+ complex + cell lysate mix 1.29x10-3 1.13x10-3 1.21x10-3 
c.)  Apo+ complex+ 50k and more 1.23x10-3 1.41x10-3 1.32x10-3 
d.)  Apo+ complex+ 50k and less 1.02x10-3 7.924x10-4 9.062x10-4 
e.)Apo+ complex+ cell lysate mix+ HSP90  1.60x10-3 1.02x10-3 1.31x10-3 
f.)  Apo+ complex+ HSP90 1.48x10-3 1.10x10-3 1.29x10-3 
g.)  Apo+ complex+ 50k and more+ HSP90 1.16x10-3 1.19x10-3 1.175x10-3 
h.)  Apo+ complex+ 50k and less+ HSP90 1.06x10-3  1.06x10-3 
 
Table 3.1. The Koff values for each different combination were represented in the table 3.1. 
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Fig.3 8. The above figure shows the effect of Hsp90 and macrophage cell lysate on heme transfer 
of GAPDH-heme complex. It shows very slight increase in rate of heme transfer when Hsp90 and 
also with macrophage cell lysate of 50kda and high compared to GAPDH-heme complex.   
 
Effect of different doses of cell lysate on rate of heme transfer from GAPDH-
heme complex to apomyoglobin: 
We examined dose response curve of cell lysate with maintaining same 
concentration of GAPDH-heme complex and apomyoglobin and the only variable 
is cell lysate protein concentration. No substantial change was observed on the 
rates of heme transfer with varying concentrations of cell lysate. 
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Fig.3.9. Comparison of rate of heme transfer when different concentration of macrophage cell 
lysate added to GAPDH-heme complex. The result shows that there was no substantial effect on 
rate with amount of cell lysate.  
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3.2 Tryptophan quenching:  
This is used to check the binding between 2 proteins or 2 ligands. Here we tested 
the binding between different GAPDH with heme. Fig.3.10 shows a representative 
titration quenching experiment with different doses of heme. The result shows that 
there was strong binding between rabbit GAPDH and heme when compared with 
human GAPDH. The mutants show that there was not much difference in amount 
or strength of binding compared to human wild type. The mutants which we 
considered here were cysteine 152 and lysine 227 which were available in lab.  
 
 
 
 
Fig.3.10. Above graph shows the quenching of fluorescence when adding increasing amounts of 
heme to GAPDH. 
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Fig.3.11. Above graph shows that rabbit GAPDH has more affinity towards heme compared to 
human GAPDH and there is no substantial difference between different mutants of human 
GAPDH although lysine 227 mutants appears to have slightly more competent binding. 
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3.3 S-Nitrosylation of GAPDH, its effect on activity and rate of heme delivery: 
Previous work from our lab (9) has shown that by nitrosylating GAPDH the heme 
binding capacity of GAPDH was reduced. Based on this finding, I set out to 
investigate the effect of S-nitrosylation on the ability of GAPDH to transfer its 
heme into apomyoglobin. GSNO was used as NO donor to nitrosylate the 
GAPDH. The amount of nitrosylation is determined by the Saville’s method which 
uses the Griess reagents. The activity is also used to check the nitrosylation of 
cysteine 152 as it is the active residue in GAPDH. GAPDH was nitrosylated as per 
the published protocol and the activity assay was performed before and after 
nitrosylation and also after incubation with heme. We also determined the rate of 
heme transfer to check the effect of nitrosylation on heme transfer of GAPDH. 
The results are shown in Fig.3.12. 
   
Fig.3.12. The graph shows that there was decrease in activity as protein gets nitrosylated. The 
heme does not have any significant decrease in activity. 
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As shown in the above graph there was a decrease in GAPDH activity upon 
nitrosylation, addition of heme had no effect on GAPDH activity. 
Then, as described above, we measured the rates of heme transfer under these 
conditions. Similar rates were obtained for nitrosylated and non-nitrosylated 
proteins. . The extent of nitrosylation of our GAPDH preparation is determined by 
Saville’s method. The level of nitrosylation under these conditions was very less 
(~15%). Dose response curve was performed to increase the extent of 
nitrosylation. No improvement in the extent of nitrosylation was obtained.  
 
3.4 Nitrosylation and factors affecting the nitrosylation: 
Physiological NO donor Cys-NO was used, which was prepared in laboratory by 
mixing sodium nitrite and L-cysteine with DTPA as described in method. We used 
bovine serum albumin to check the amount of nitrosylation as BSA was less 
expensive and easily available. Range of concentration of Cys-NO 10, 20, 30 and 
up to 150 fold was used with respect to protein concentration, low levels of 
nitrosylation (~30%) was obtained.  Freshly prepared BSA and frozen BSA was 
treated with 100-fold excess DTT to check if any disulphide bonds present are 
interfering with extent of nitrosylation and excess DTT was removed by PD-10 
columns. There was dramatic increase in the levels of nitrosylation by reducing 
BSA with DTT both in fresh as well as frozen samples.  A similar finding was 
reported previously (33). 
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Fig.3.13. The difference in amount of nitrosylation of normal BSA and DTT treated BSA. The 
result shows that it has a substantial difference in amount of nitrosylation which indicates that the 
presence of disulphide bonds was interfering with the process of nitrosylation.  
 
GAPDH was reduced with 100 fold excess DTT to check if any disulphide bonds 
are interfering with extent of nitrosylation. DTT treated and untreated GAPDH 
shows same amount of nitrosylation after nitrosylating with Cys-NO. The result 
suggests that there was no effect of DTT indicating that there were no disulphide 
bonds and dose 20 fold of nitrosylation donor shows having better nitrosylation.  
We examined other factors which may have effect on nitrosylation of GAPDH like 
dose of NO donor and presence of reducing agents (example: DTT). Nitrosylation 
is light sensitive. Range of concentrations 10, 20, 50, 200 fold Cys-NO to that of 
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GAPDH was considered. The result suggests that there were no disulphide bonds 
which are interfering with nitrosylation and nitrosylation is not dose dependent.  
 
Fig.3.14. The amount of nitrosylation happening with increasing amount of nitrosylation donor 
and comparison with and with out adding DTT. The result suggests that there is no substantial 
difference on extent of nitrosylation.  
 
We focused on dose response curve of different GAPDH to understand the affect 
of amount of nitrosylation donor on extent of nitrosylation on human recombinant 
wild-type GAPDH, c152s mutant human GAPDH and rabbit muscle GAPDH.  
 
3.5 Dose response curves for S-nitrosylation of different GAPDH variants: 
Rabbit GAPDH:  
In case of rabbit GAPDH, the result shows no effect of dose of nitrosylation donor 
on extent of nitrosylation (Fig.3.15). The fold of Cys-NO which was considered, 
was 1, 2, 3, 5, and 10, 20 and 50-fold to that of protein concentration 
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Fig.3.15. Comparing different doses of nitrosylation donor with same amount of rabbit muscle 
GAPDH. The results show that there was no substantial effect on the extent of nitrosylation 
though slightly higher nitrosylation was observed at 20 fold. 
 
Human GAPDH: 
In the case of human GAPDH the extent of nitrosylation is directly proportional to 
Cys-NO fold (Fig.3.15). The amount of nitrosylation was increased with amount 
of Cys-NO used.  The fold of Cys-NO which were considered, were 1, 2, 3, 5, 10, 
20 and 50 fold to that of protein concentration.    
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Fig.3.16. Comparing different doses of nitrosylation donor with same amount of Human 
GAPDH. The result shows that the nitrosylation is increasing with the amount of nitrosylation 
donor which shows that it has maximum effect at 50fold. 
 
C152s GAPDH:  
In the case of human C152S mutant GAPDH the extent of nitrosylation was 
directly proportional to Cys-NO fold. Surprisingly, we found that the extent of 
nitrosylation was similar to human wild-type GAPDH, in vivo experiments from 
our lab suggests that nitrosylation occurs only at cysteine 152, here with out 
cysteine 152 similar extent of nitrosylation was observed. Possibilities include that 
S-nitrosylation is specific in vivo, which was not observed in vitro. Protein DNA 
sequencing was performed to confirm the presence of mutation. Wild type has the 
activity and C152S has none, as expected. 
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  SNO per 1 µM monomer 
 SNO per 1 µM monomer 
 SNO per 1 µM monomer 
  
Fig.3.17. Comparing different doses of nitrosylation donor with same amount of Human c152s 
GAPDH, the result shows that the nitrosylation is increasing with the amount of nitrosylation 
donor which shows that it has maximum effect at 50fold. 
 
3.6 Stability of nitrosylated GAPDH: 
We examined the stability of nitrosylated GAPDH with time and the effect of 
heme on stability of nitrosylated GAPDH. GAPDH was nitrosylated using 50-fold 
excess Cys-NO. The stability tests were conducted at 0, 2, 6, 18, 48, 72, 120 
hours. Stability test for nitrosylated-GAPDH was performed at two conditions: 
room temperature and 4oC. We took both rabbit GAPDH and human GAPDH to 
compare the results.  
53 
 
 
 
Fig.3.18.The amount of nitrosylation at different time points at room temperature and 4 degree 
centigrade with and without heme. As the time progresses the amount of nitrosylation decreases 
which is drastic at room temperature and less at 4 degree centigrade. The proteins which were 
considered here are human and rabbit GAPDH and the nitrosylation donor used was 50 fold.  
 
From the above graph (Fig.3.18) it is observed that levels of nitrosylation 
decreased with time and at room temperature the nitrosylation drops down 
drastically. Human GAPDH at 4oC is stable for up to 5 days the presence of heme 
does not have any effect on the stability of rabbit and human nitrosylated GAPDH. 
From the above experiment one thing that is confirmed is that temperature plays 
major role in the stability of nitrosylated GAPDH besides light. 
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Effect of pH on S-nitrosylation of GAPDH: 
The other factor which I considered was the pH as we are utilizing a dose of 50-
fold excess Cys-NO to that of protein concentration. Here the pH’s which I 
considered was near physiological pH’s which are 6, 7, and 8.The effect was 
found to be as the pH increases the nitrosylation of GAPDH increases in case of 
rabbit and in case of human it is shown to have increased yields of nitrosylation at 
acidic and alkaline and remain less at neutral pH at 7. Here 3 buffers of different 
pH were made and GAPDH solutions were made with those buffers. Then 50fold 
Cys-NO was added and rest is as usual and PD-10 columns were also equilibrated 
with respective buffers. Altogether, these results suggest that human and rabbit 
GAPDH present differences in their ability to undergo S-nitrosylation at different 
pH’s, which may be due to the extra exposed cysteine present at 282 position in 
rabbit GAPDH. 
 
Fig.3.19. Comparing the amount of nitrosylation on rabbit muscle GAPDH which are nitrosylated 
at 3 different pH 6, 7 and 8. The result shows that the degree of nitrosylation slightly increases 
with increase in pH which shows maximum nitrosylation at pH 8. 
55 
 
 
 
Fig.3.20. Comparing the amount of nitrosylation on human GAPDH which were nitrosylated at 3 
different pH’s 6, 7 and 8. The result shows that the degree of nitrosylation is independent of pH. 
 
Effect of oxygen on the efficiency of S-nitrosylation of GAPDH: 
We examined the affect of oxygen on extent of nitrosylation (As oxygen can cause 
free thiol oxidation). Nitrosylation was performed in anaerobic chamber to 
determine the affect of oxygen on extent of nitrosylation of GAPDH. All the 
buffers and reagents and also PD-10 columns were degassed by using nitrogen 
prior to experiment. We considered 3 different pH’s 6, 7 and 8. The result from 
Fig.3.21, which when compared to Fig.3.20 suggests that there were no oxidized 
cysteines in human GAPDH. A comparison of aerobic and anaerobic conditions 
shows no difference in the yield of nitrosylation.  
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Fig.3.21. Comparing the amount of nitrosylation on human GAPDH in absence of oxygen which 
were nitrosylated at 3 different pH 6, 7 and 8. The result shows that the amount of nitrosylation is 
independent of pH and oxygen.  
 
Finally, we considered whether or not the use of HEPES buffer was most 
appropriate for these experiments. Although not previously reported we suspected 
that tertiary amines may interfere with nitrosylation by reacting with Cys-NO. We 
also checked PD-10 column effectiveness in terms of removing unreacted Cys-
NO. So here we incubated HEPES with 50ul which generally is 50fold or more 
when considered protein for 30-45 minutes and passed it through the PD-10 
columns and found negligible amount of NO. By this experiment we confirmed, 
HEPES buffer has no effect on S-nitrosylation and PD-10 gel filtration columns 
blocks unreacted NO donor.    
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3.7 Estimation of the extent of s-nitrosylation on each individual cysteine by 
mass spectrometry: 
Extent of nitrosylation on each individual cysteine residue was identified by mass 
spectrometry as we have seen C152S mutant GAPDH was getting nitrosylated, 
which was different from in vivo data. SNOB technology was used as this is a 
single step reaction which directly involves labeling with SNOB reagent without 
using any free thiol blocker and ascorbate to reduce and acetone precipitation steps 
as in case of biotin switch technique. 
The result in Fig. 3.22 represents that SNOB reagent reacts with both nitrosylated 
and non-nitrosylated GAPDH and SNOB control does not react.  
GAPDH
 
Fig.3.22. The immunoblotting representing SNOB reagent and control. Human wild type and 
human C152S mutant GAPDH nitrosylated and non nitrosylated were mixed with SNOB reagent 
and control at 60 degree centigrade and immunoblotted. The result shows that the SNOB reagent 
or the control has no specificity for nitrosylated and non nitrosylated GAPDH. 
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The result in Fig. 3.22 represents that SNOB reagent reacts with both nitrosylated 
and non-nitrosylated GAPDH and SNOB control does not react. Different 
conditions were examined, where only nitrosylated GAPDH reacts with SNOB 
reagent. SNOB was reacted with nitrosylated and non-nitrosylated GAPDH 60o C 
for 30 minutes, 40o C for 30 minutes and exposed to high intensity light for 2-3 
minutes [The patent document for use of SNOB reagent suggested to test 2 
temperatures]. Same concentration of protein was loaded onto each well in gel. 
The result below shows that SNOB technology has no specificity for nitrosylated 
and non-nitrosylated GAPDH.  
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Fig.3.23. The immunoblotting representing SNOB reagent and control. Human wild type and 
human C152S mutant GAPDH nitrosylated and non nitrosylated were mixed with SNOB reagent 
and control at 3 different conditions 60 degree centigrade, 40 degree centigrade and high beam 
light for 2 minutes and immunoblotted. The result shows that the SNOB reagent or the control 
has no specificity for nitrosylated versus non nitrosylated GAPDH. 
 
 
Biotin switch technique was used to identify the extent of nitrosylation on each 
individual cysteine with little modification; MMTS (methyl methane 
thiosulfonate) was replaced with NEM (N-ethylmaleimide). Biotin-HPDP was 
used as labeling agent; quantification of biotin-HPDP was done by mass 
spectrometry. Human GAPDH and rabbit GAPDH were used. The sample buffer 
used here is non-reducing buffer with no boiling. Same amount of sample was 
loaded onto each well. The controls used here was non-nitrosylated GAPDH. The 
gel electrophoresis was done until protein bands get separated. The gel is then 
subjected to mass spec analysis. Of the four cysteines in rabbit GAPDH three were 
identified and the cysteine at 282 was not identified. In human GAPDH 3 
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cysteines were identified in the Carbamidomethylated, NEM, and biotin modified 
form.  
1.) Human GAPDH: C152, C156, and C247. 
The T146-162 peptide, IISNASCTTNCLAPLAK, contains the Cys150 and 
Cys152 residues and was identified in several forms including the 
carbamidomethylated, NEM, and biotin modified form. The only biotin form of 
the IISNASCTTNCLAPLAK peptide identified in these experiments was the 
C+559 form. The C247 peptide, VPTANVSVVDLTCR, was also identified in the 
carbamidomethylated, NEM, biotin 559, and biotin 525 forms. 
-While three sites of C+Biotin were identified in these bands, ratios of the 
CBiotin/ (CNEM+C) may be giving a first estimation to the degree of 
modification at these sites. These ratios for human GAPDH 
Cys152:Cys156:Cys247 are 0.0021:0.0003:0.0017 indicating that the preference 
of NO modification is Cys152 ~ Cys247 > Cys156  
2.) Rabbit GAPDH: C150, C154, and C245. 
The results from the rabbit samples were very similar to the human samples with 
each Cys Residue identified in the C, CNEM, and CBiotin forms. While both 
C150 and Cys154 were identified in the biotinatlyed (559) form Cys150 appears to 
be modified to a greater extent than Cys154. In addition, only the Cys150 residue 
was identified in the CBiotin (525) form. The Cys245 residue was also identified 
in all four forms. Consistent with the results of human GAPDH the C+525 Da 
form is almost an order of magnitude lower in abundance than the C+559 Da 
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form. In rabbit the ratios for Cys150:Cys154:Cys245 are 0.003:0.001:0.05 
indicating that modification preference is Cys247>Cys150>Cys154. The Cys282 
is not identified both by trypsin and chymotrypsin digestion as the peptide is 
missing. 
Amount of nitrosylation from mass spectrometry experiments was found to be low 
which when compared to extent of nitrosylation determined by Saville’s method. 
Factors affecting amount of nitrosylation during the process were examined. The 
first factor which was considered was the choice of thiol blocker, MMTS and 
NEM. MMTS and NEM were reacted with nitrosylated GAPDH. The excess 
NEM or MMTS was removed by acetone precipitation. Nitrosylation was 
measured by saville’s method before and after thiol blocker treatment. The result 
indicates MMTS treatment precipitates GAPDH; however NEM treatment does 
not precipitate protein and or loss of nitrosylation.   
The next factor which was considering was biotin HPDP. Biotin-HPDP was 
replaced with alkylating agent iodoacetamide. The results were described below.  
Human GAPDH: 
The only form the Cys152, Cys156, and Cys247 peptides identified in the 
unmodified human GAPDH is the CNEM form, while both the C and CNEM 
forms were identified in the +NO samples. If we assume that all of the 
carbamidomethylated modified Cys residues are derived from Cys-NO and no 
other forms of this residue are present, than we can utilize these targeted 
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experiments to determine the %Cys-NO for each residue. For human GAPDH 
these values are 93% for Cys152, 42% for Cys156 and 14% for Cys247.  
Rabbit GAPDH: 
 The results from the rabbit GAPDH differ from human GAPDH in that both the 
carbamidomethylated and CNEM forms were identified in the unmodified and 
+NO samples, however, the amount of the carbamidomethylated forms in the 
unmodified samples are small (less than 5%). At this time the source of these 
residues is unclear, however, these residues may represent free thiol not blocked 
with NEM. Despite this, the degree of modification at C150, C154, and C245 can 
be determined from these experiments. For rabbit GAPDH the %C-NO values are 
98% for Cys150, 96% for Cys154, and 75% for Cys245. All of these values are 
higher than that observed for human GAPDH.  
 
Fig. 3.24. The gel that was subjected to mass spectrometric analysis. 
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Table.3.2.The extent of nitrosylation that has occurred at 3 cysteines in human GAPDH, the result 
shows that c152 is the most susceptible with 93%, c156 with 42% nitrosylation and c247 with 
14% nitrosylation.  
 
Rabbit GAPDH + NO Rabbit GAPDH - NO
  
Table.3.3.The extent of nitrosylation that occurred at 3 cysteines in rabbit GAPDH as the fourth 
cysteine was not detectable. The amount of nitrosylation found to be same on Cys150 and Cys154 
and slightly more compared to Cys245.  
 
From the above experiment we identified that all the cysteine residues present in 
GAPDH underwent differential nitrosylation, in the preference order 
Cys152>Cys156>Cys247 in human GAPDH. In case of rabbit GAPDH S-
nitrosylation is in the order of Cys150~Cys154>Cys247.  
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3.8 Making different GAPDH mutants and their effect on heme delivery after 
S-nitrosylation: 
In parallel we did different point mutations, by mutating cysteine in GAPDH to 
further investigate whether s-nitrosylation of specific cysteine residues were 
involved in heme transfer to apomyoglobin. Cysteine was replaced with serine. 
There are 3 cysteines in human GAPDH at positions 152, 156 and 247. C152S 
mutant was available in the lab. We made single point mutations at cysteines 156 
and 247 sites. Double mutations include 152/247, where only cysteine 156 is 
present, 156/247 where only cysteine 152 is present and 152/156 where only 
cysteine 247 is present. We made a triple mutant where all the cysteines in 
GAPDH were replaced by serine residues.  
Once the mutations were done, yield of different transformation colonies was 
checked.  The results were shown below. The colonies with maximum protein 
concentration were used for purification of different mutants of GAPDH. 
Purification yields vary from 5 to 15 mg per 4 litre of culture of E.coli.  
Western blot of mutants: The results of experiment of the different GAPDH were 
given in Fig.3.25. 
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Fig.3.25. In case of cysteine 156 mutant 3 colonies expressed equally, in case of cysteine 156 247 
double mutant 2nd colony has more expression, in case of triple mutant 3 colonies express 
equally. In case of cysteine 152/156 3rd colony has maximum expression; in case of cysteine 
152/247 1st colony has maximum expression.  
 
 
As described in our GAPDH purification protocol different mutants of GAPDH 
were purified and the purity was examined by gel electrophoresis. The result 
below shows that all the proteins were good in terms of purity (>85%).  
C152/247S C152/156S 
2 1 3 1 2 3 
GAPDH+ 
GST 
c156s C156/247s C152/156/247s 
1            2          3          1           2          3           1           
GAPDH
+GST 
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ig.3.26. The gel represents different mutants of GAPDH, purity is ~85%.  
 
The rate of heme transfer was examined from different mutants of GAPDH to 
apomyoglobin. We considered nitrosylation as a factor to check which mutant has 
a detectable difference on the rate of heme transfer after getting nitrosylated. By 
this means we can investigate which nitrosylated cysteine has an effect on the rate 
of heme transfer.  
 
 
F
 
 
Fig.3.27. In the above graph rate of heme transfer from non-nitrosylated GAPDH was represented 
by red bar and black bar represents rate of heme transfer from nitrosylated GAPDH. The result 
suggest that there was no affect of nitrosylation on rate of heme transfer other than 2 mutants 
C152/156S and C156S  
 
The above result suggests that there was no affect of S-nitrosylation on the rate of 
heme transfer other than 2 mutants a.) C152/156S where both cysteines 152 and 
156 were replaced with serines and only cysteine 247 is present. Upon 
nitrosylation the rate of heme transfer doubled that of the corresponding non-
nitrosylated protein but the difference is not substantial b.) C156S which has 
cysteines 152 and 247 also shows double the rate of heme transfer but the 
difference is not substantial.  
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CHAPTER IV 
CONCLUDING REMARKS AND FUTURE INVESTIGATIONS 
 
Based on the results presented in this thesis, we conclude that S-nitrosylation of 
cysteines in human GAPDH has no affect on rate of heme transfer to 
apomyoglobin. The factors that affect the extent of nitrosylation included dose of 
nitrosylation donor in case of human GAPDH and pH in the case of rabbit 
GAPDH (alkaline pH increased the extent of nitrosylation). Nitrosylated GAPDH 
was more stable at 4oC than at room temperature. The presence of reducing agents 
or oxygen did not affect the yield of nitrosylation. The mass spectrometry results 
suggest that the extent of nitrosylation on each individual cysteine is species-
specific as the cysteines present in rabbit and human GAPDH’s displayed different 
extents of nitrosylation. In case of human GAPDH the extent of nitrosylation is in 
order of Cys152 (93%)>Cys156 (42%)>Cys247 (14%), whereas in rabbit GAPDH 
the extent of nitrosylation is in order of Cys150 (98%) ~Cys156 (96%)>Cys247 
(75%). From 
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here, there are a few topics that can be further explored in order to fully 
understand the mechanism of heme transfer from GAPDH. 
a.) Even though we have not seen the effect of S-nitrosylation on rate of heme 
transfer from GAPDH, there could be other properties of GAPDH which may 
possibly be affected. We could explore the effect of S-nitrosylation on the binding 
affinity (Kon) of heme to GAPDH. We could explore how the protein-protein 
interactions of GAPDH with heme-protein differ, once the GAPDH is S-
nitrosylated. 
b.) We could explore how the properties of heme are affecting the rate of heme 
transfer after nitrosylation. This can be tested by using different heme analogues 
like meso-heme, deutero-heme, Zn+2-heme and Co+2-heme. By investigating this, 
we can examine whether the structural or chemical properties of heme have any 
effect on rate of heme transfer after nitrosylation. 
c.) We could test GAPDH from other organisms to see whether the specific 
nitrosylation has any effect on the rate of heme transfer. This can be examined 
using site directed mutagenesis on cysteine residues of rabbit and bacterial 
GAPDH’s. One could investigate whether, other organism GAPDH’s behave in a 
similar way after nitrosylation. 
d.) We have to yet to identify which aminoacids are ligating the heme. Some of 
our preliminary data suggest it may be histidine or cysteine. Recently, our lab has 
observed preliminarily heme binding is not reduced after mutating cysteines, 
therefore ruling out the cysteines as ligands. This can be done by mutating the 
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histidines and see whether these mutations has any effect on heme binding 
property of GAPDH. Histidine specific chemical modification can also be 
considered as an alternative. 
The results from this work and future investigations can help better understand the 
mechanism of heme transfer from GAPDH to many physiologically relevant apo-
protein targets such as apo-NOS, apo-cytochrome p450.   
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